Entering the company, the reporter got an initial impression that PRO was modern and neat, which mirrors the cutting-edge technology development that PRO is committed to.

Manager Lin Xiaoqiu introduces PRO products to the reporter

       PRO successfully launched a large scale non-invasive focused ultrasound system for gynecological treatment in 2012, and also obtained the CE certification for the European market in the same year. Lin Xiaoqiu said the company has also received some international market recognition and is expected to receive new orders in the European market this year.

　　It is well known that the development and promotion of focused ultrasound technology requires a long incubation period, especially for new medical technologies for human health. In this regard, Lin Xiaoqiu also admitted that technology development in the industry is difficult. Non-invasive treatment is not really a must-have technology. Experts and scholars did not classify it as an alternative new technology in the early days, which makes the technology not available today as a necessary treatment for malignant tumors.

      Manager Lin emphasized, "Technology is our lifeline. As a high-tech enterprise, we can only have a future if we ensure high-quality R&D and innovation."

　　"The company currently spends more than 20 percent of its revenue on research and development, which should be the highest in the industry." In addition to the massive investment in R&D, Lin also talked about the company's promotion of hiring young people. "Most of our employees are young people with strong execution, which gives us an advantage in innovative product development."

　　In addition to creative young employees, PRO cannot achieve innovative R&D without the scientific support of higher education institutions. Data shows that since its establishment, PRO has cooperated with the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences and a number of universities. PRO has already built a scientific product development system and a stable and efficient R&D team. The company has also carried out scientific research cooperation with a number of hospitals on the focused ultrasound gynecological treatment system, which have achieved good clinical effects.

 "We were the only company that obtained the registration certificate last year. In recent years, there have been no new products in the industry other than our products," said Lin Xiaoqiu.

　　When talking about the company vision, Lin said that PRO wants to be the first listed company in the industry. PRO hopes to gain an upper hand in the industry and promote ultrasound treatment to benefit more patients.

　　Lin said that the implementation of the STAR market has brought great opportunities to the company. The company will proactively prepare and try to get listed on the STAR market so that it can achieve better development.

　　He also said that going public is not the main goal PRO is pursuing, and that PRO is always committed to allowing patients to receive treatment with dignity.

According to Lin, PRO will dedicate greater efforts to ultrasound-guided intervention under the next five-year plan. Meanwhile, PRO will strive to make more breakthroughs in the substantive clinical treatment of pancreatic cancer in the near future. In addition, PRO has been thinking about the treatment of chronic pain. "We must do our job well and keep developing more products and indications to benefit more patients," Lin said.